A preventive AD vaccine developed through this strategy could stimulate long-lasting antibodies in individuals at risk of AD, potentially inhibiting the aggregation/accumulation of pathological Aβ and tau proteins and delaying the onset of dementia. Here, MAPT is linked to Alzheimer disease.